Lilly Canada finalizes a major deal with pCPA, advancing access to a new UC treatment across Canada
Small teams specialist outlines what smaller Canadian employers are doing to manage, and the lessons they hold for larger organizations
Identifying areas where drug costs are rising, and the unique challenges posed by GLP-1 drugs
Health Canada approves TRIKAFTA for additional CF mutations, increasing treatment options for patients
Pfizer plans clinical trials for a once-a-day weight-loss pill after discontinuing the twice-daily version
SVP of Benefit Services at NFP explains the areas where costs are rising and the options plan sponsors now have to deal with these increases
